Eosinophilic Esophagitis (Gastrointestinal) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis – Drugs In Development, 2021, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 4, 3, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Adare Pharma Solutions

Allakos Inc

Arena Pharmaceuticals Inc

Banner Life Sciences LLC

Bristol Myers Squibb Co

Calypso Biotech SA

DBV Technologies SA

Dr. Falk Pharma GmbH

Ellodi Pharmaceuticals

EsoCap AG

GlaxoSmithKline Plc

Humanigen Inc

Kyowa Kirin Co Ltd

Landos Biopharma Inc

Morphic Therapeutic Inc

Nexeos Bio

Pantherics Inc

Quorum Innovations LLC

RAPT Therapeutics Inc

Regeneron Pharmaceuticals Inc

Revolo Biotherapeutics Ltd

Suzhou Connect Biopharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Introduction

Eosinophilic Esophagitis - Overview

Eosinophilic Esophagitis - Therapeutics Development

Eosinophilic Esophagitis - Therapeutics Assessment

Eosinophilic Esophagitis - Companies Involved in Therapeutics Development

Eosinophilic Esophagitis - Drug Profiles

Eosinophilic Esophagitis - Dormant Projects

Eosinophilic Esophagitis - Discontinued Products

Eosinophilic Esophagitis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Eosinophilic Esophagitis – Pipeline by Adare Pharma Solutions, 2021

Eosinophilic Esophagitis – Pipeline by Allakos Inc, 2021

Eosinophilic Esophagitis – Pipeline by Arena Pharmaceuticals Inc, 2021

Eosinophilic Esophagitis – Pipeline by Banner Life Sciences LLC, 2021

Eosinophilic Esophagitis – Pipeline by Bristol Myers Squibb Co, 2021

Eosinophilic Esophagitis – Pipeline by Calypso Biotech SA, 2021

Eosinophilic Esophagitis – Pipeline by DBV Technologies SA, 2021

Eosinophilic Esophagitis – Pipeline by Dr. Falk Pharma GmbH, 2021

Eosinophilic Esophagitis – Pipeline by Ellodi Pharmaceuticals, 2021

Eosinophilic Esophagitis – Pipeline by EsoCap AG, 2021

Eosinophilic Esophagitis – Pipeline by GlaxoSmithKline Plc, 2021

Eosinophilic Esophagitis – Pipeline by Humanigen Inc, 2021

Eosinophilic Esophagitis – Pipeline by Kyowa Kirin Co Ltd, 2021

Eosinophilic Esophagitis – Pipeline by Landos Biopharma Inc, 2021

Eosinophilic Esophagitis – Pipeline by Morphic Therapeutic Inc, 2021

Eosinophilic Esophagitis – Pipeline by Nexeos Bio, 2021

Eosinophilic Esophagitis – Pipeline by Pantherics Inc, 2021

Eosinophilic Esophagitis – Pipeline by Quorum Innovations LLC, 2021

Eosinophilic Esophagitis – Pipeline by RAPT Therapeutics Inc, 2021

Eosinophilic Esophagitis – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Eosinophilic Esophagitis – Pipeline by Revolo Biotherapeutics Ltd, 2021

Eosinophilic Esophagitis – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2021

Eosinophilic Esophagitis – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Eosinophilic Esophagitis – Dormant Projects, 2021

Eosinophilic Esophagitis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports